Moody’s considers cutting Lilly debt rating
As early as next year, Moody’s Investors Service could lower its debt rating on Eli Lilly and Co. because of the looming patent expiration of Lilly’s top-selling drug, Zyprexa. In a quarterly snapshot of the drug industry, Moody’s said it will take a hard look at any pharmaceutical company with a blockbuster drug set to […]